These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35234552)

  • 1. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
    Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K
    Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
    Müller-Ladner U; Dignass A; Gaffney K; Jadon D; Matucci-Cerinic M; Lobaton T; Carron P; Gisbert JP; Pande I; Utzinger M; Addison J
    BioDrugs; 2023 Nov; 37(6):873-889. PubMed ID: 37632666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.
    Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P
    Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
    Cingolani L; Barberio B; Zingone F; Ferronato A; Bertani L; Costa F; Bodini G; Demarzo MG; Melatti P; Gubbiotti A; Massimi D; Casadei C; D'Incà R; Savarino EV
    Sci Rep; 2021 May; 11(1):10368. PubMed ID: 33990652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
    Poquet-Jornet JE; Ibáñez-Sala I; Garrigues-Pelufo T; Munilla-Das A; Valdivia-Pérez A; Carrera-Hueso FJ
    Farm Hosp; 2024 Apr; ():. PubMed ID: 38570210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
    Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.
    Tapete G; Bertani L; Pieraccini A; Lynch EN; Giannotta M; Morganti R; Biviano I; Naldini S; Mumolo MG; De Nigris F; Calella F; Bagnoli S; Minciotti M; Maltinti S; Rentini S; Ceccarelli L; Lionetti P; Milla M; Costa F
    Inflamm Bowel Dis; 2022 Jan; 28(1):62-69. PubMed ID: 33570142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
    Barberio B; Cingolani L; Canova C; Barbieri G; Sablich R; Urbano MT; Bertani L; Costa F; Bodini G; Demarzo MG; Ferronato A; Buda A; Melatti P; Massimi D; Savarino EV; Zingone F
    Therap Adv Gastroenterol; 2021; 14():17562848211031420. PubMed ID: 34349836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis.
    Song SH; Woo SJ
    Ocul Immunol Inflamm; 2024 Oct; 32(8):1755-1759. PubMed ID: 38194436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS).
    Young D; Harris C; Rahmany S; Iria I; Gonçalves J; Addison J; Harvey J; Latter S; Cummings F
    Int J Clin Pharm; 2024 Oct; 46(5):1091-1101. PubMed ID: 38734866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study.
    Ribaldone DG; Tribocco E; Rosso C; Armandi A; Vernero M; Bugianesi E; Astegiano M; Saracco GM; Caviglia GP
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease.
    Viscido A; Latella G
    Rev Esp Enferm Dig; 2021 Feb; 113(2):154-155. PubMed ID: 33207902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.